AEON Biopharma (AEON) Projected to Post Earnings on Wednesday

AEON Biopharma (NASDAQ:AEON) is projected to issue its results before the market opens on Wednesday, May 20th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

AEON Biopharma Trading Up 0.6%

AEON stock opened at $0.89 on Wednesday. AEON Biopharma has a 1 year low of $0.46 and a 1 year high of $1.45. The company has a fifty day simple moving average of $1.01 and a 200 day simple moving average of $1.01. The firm has a market cap of $22.44 million, a PE ratio of 4.93 and a beta of 0.66.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AEON Biopharma stock. Geode Capital Management LLC raised its stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the quarter. Geode Capital Management LLC owned 0.51% of AEON Biopharma worth $66,000 as of its most recent filing with the SEC. 22.78% of the stock is owned by hedge funds and other institutional investors.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.